Halozyme Therapeutics Inc. (HALO)

19.87
NASDAQ : Health Technology
Prev Close 19.28
Day Low/High 19.28 / 19.98
52 Wk Low/High 11.41 / 21.13
Avg Volume 1.17M
Exchange NASDAQ
Shares Outstanding 142.36M
Market Cap 2.74B
EPS 0.50
P/E Ratio 42.84
Div & Yield N.A. (N.A)

Latest News

Shopify, Kinder Morgan, Pfizer: 'Mad Money' Lightning Round

Shopify, Kinder Morgan, Pfizer: 'Mad Money' Lightning Round

Jim Cramer highlights Shopify, Kinder Morgan, Thermo Fisher Scientific, Radius Health, Merck, Pfizer and more.

Halozyme Therapeutics Reaches Analyst Target Price

In recent trading, shares of Halozyme Therapeutics Inc have crossed above the average analyst 12-month target price of $20.11, changing hands for $20.36/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Halozyme Projects 25 To 30 Percent ENHANZE Royalty Growth In 2018

Halozyme Projects 25 To 30 Percent ENHANZE Royalty Growth In 2018

CONTINUES TO EXPECT TARGET NUMBER OF PFS EVENTS IN HALO-301 REGISTRATION TRIAL TO BE REACHED IN LATE Q4

Roku, Sierra Wireless, Visa, Cimarex Energy: 'Mad Money' Lightning Round

Roku, Sierra Wireless, Visa, Cimarex Energy: 'Mad Money' Lightning Round

Jim Cramer focuses on Roku, Sierra Wireless, Visa, Cimarex Energy, First Solar, Halozyme Therapeutics.

Good Things Come to Those Who Buy: Cramer's 'Mad Money' Recap (Monday 12/18/17)

Good Things Come to Those Who Buy: Cramer's 'Mad Money' Recap (Monday 12/18/17)

Don't buy big here and don't buy all at once, but it's not too late to ride this bull to profits, says Jim Cramer.

Sage Therapeutics Skyrockets on Data for Depression Drug -- Biotech Movers

Sage Therapeutics Skyrockets on Data for Depression Drug -- Biotech Movers

The Cambridge, Mass.-based firm unveiled positive top-line results from its Phase 2 study of SAGE-217 in patients with moderate to severe major depressive disorder.

Alexion And Halozyme Enter License Agreement For ENHANZE Technology

Alexion And Halozyme Enter License Agreement For ENHANZE Technology

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Halozyme Therapeutics, Inc.

Exxon, Chevron, Cimarex Energy: 'Mad Money' Lightning Round

Exxon, Chevron, Cimarex Energy: 'Mad Money' Lightning Round

Jim Cramer is bullish on Exxon, Chevron, Cimarex Energy, Skechers USA, and Halozyme Therapeutics.

Trump Doesn't Get All the Credit: Cramer's 'Mad Money' Recap (Wed 11/8/17)

Trump Doesn't Get All the Credit: Cramer's 'Mad Money' Recap (Wed 11/8/17)

Jim Cramer says President Trump has been a great salesman, but when we look at winning stocks, it's the strong CEOs who are driving success.

Phase 3 Study Of Subcutanous Daratumumab Initiated Using Halozyme's ENHANZE Technology

Phase 3 Study Of Subcutanous Daratumumab Initiated Using Halozyme's ENHANZE Technology

-- Subcutaneous injection has potential to reduce multi-hour infusion to 5-minutes--

Spectrum Shares Surge on Data for Lung Cancer Drug -- Biotech Movers

Spectrum Shares Surge on Data for Lung Cancer Drug -- Biotech Movers

The Henderson, Nev.-based company said interim data from a Phase 2 study showed an objective response rate of 73%.

Halozyme Initiates Clinical Trial Of PEGPH20 With Anti-PDL1 Immunotherapy In Cholangiocarcinoma And Gallbladder Cancer Patients

Halozyme Initiates Clinical Trial Of PEGPH20 With Anti-PDL1 Immunotherapy In Cholangiocarcinoma And Gallbladder Cancer Patients

PEGPH20, atezolizumab Combination to be Evaluated Under Clinical Collaboration

What's Hot and What's Not: Cramer's 'Mad Money' Recap (Thursday 10/12/17)

What's Hot and What's Not: Cramer's 'Mad Money' Recap (Thursday 10/12/17)

In this sometimes fickle market, supply and demand are still at play.

Shark Bites: Market Starts Selling the News Even Before Trump Talks Taxes

Shark Bites: Market Starts Selling the News Even Before Trump Talks Taxes

Proposals are having an effect ahead of afternoon announcement.

Strong Action in Individual Stocks Starts to Feel a Bit Frothy

Strong Action in Individual Stocks Starts to Feel a Bit Frothy

It's hard to predict when momentum will slow, but it could be time to take some profits when the market is as strong as this morning.

Good Stocks Are There for the Picking

Good Stocks Are There for the Picking

Focus on what could go right.

There Are Good Opportunities in Stock Picking

There Are Good Opportunities in Stock Picking

The indices may need a rest, but stock-pickers have an edge.

Halozyme Jumps on Immuno-Oncology Deal with Bristol-Myers

Halozyme Jumps on Immuno-Oncology Deal with Bristol-Myers

Pharma giant aims to develop cancer drug delivery technology. Halozyme shares are up more than 16% in pre-market trading.

TheStreet Quant Rating: D (Sell)